SIX3, SIX homeobox 3, 6496

N. diseases: 117; N. variants: 14
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4021638
Disease: Absent nasal septal cartilage
Absent nasal septal cartilage 		0.100 Biomarker disease HPO
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.010 AlteredExpression group BEFREE Moreover, SIX3 mRNA expression was associated with significantly improved overall survival (OS) and progression-free survival (PFS) in adenocarcinoma patients and patients with bronchioloalveolar carcinoma (BAC) features. 23977152 2013
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.010 AlteredExpression disease BEFREE Association of SIX3 expression levels with clinical outcomes of patients with lung adenocarcinoma was evaluated using the Kaplan-Meier method and a multivariate Cox proportional hazards regression model. 23977152 2013
CUI: C1846223
Disease: Adrenal hypoplasia
Adrenal hypoplasia 		0.100 Biomarker phenotype HPO
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma 		0.010 AlteredExpression disease BEFREE Epigenetically controlled Six3 expression regulates glioblastoma cell proliferation and invasion alongside modulating the activation levels of WNT pathway members. 28643150 2017
CUI: C0175754
Disease: Agenesis of corpus callosum
Agenesis of corpus callosum 		0.100 Biomarker disease HPO
CUI: C0431363
Disease: Alobar Holoprosencephaly
Alobar Holoprosencephaly 		0.500 Biomarker disease CTD_human Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. 10369266 1999
CUI: C0431363
Disease: Alobar Holoprosencephaly
Alobar Holoprosencephaly 		0.500 GermlineCausalMutation disease ORPHANET
CUI: C0266362
Disease: Ambiguous Genitalia
Ambiguous Genitalia 		0.100 Biomarker disease HPO
CUI: C4021249
Disease: Anterior pituitary agenesis
Anterior pituitary agenesis 		0.100 Biomarker phenotype HPO
CUI: C1840077
Disease: Anteverted nostril
Anteverted nostril 		0.100 Biomarker phenotype HPO
CUI: C0078982
Disease: Arhinencephaly
Arhinencephaly 		0.300 Biomarker disease CTD_human Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. 10369266 1999
CUI: C0265740
Disease: Arrhinia
Arrhinia 		0.100 Biomarker disease HPO
CUI: C0004096
Disease: Asthma
Asthma 		0.100 Biomarker disease HPO
CUI: C0004114
Disease: Astrocytoma
Astrocytoma 		0.010 AlteredExpression disease BEFREE Importantly, interactions between AURKA and AURKB stabilize and protect AURKA/B from degradation, and overexpression of SIX3 does not affect these interactions; SIX3 also acts as a tumor suppressor, and it increases p53 activity and expression at the post-translational level by the negative regulation of AURKA or AURKB, reduces the events of numerical centrosomal aberrations and misaligned chromosomes, and significantly inhibits the proliferation, invasion, and tumorigenesis of astrocytoma in vitro and in vivo. 28595628 2017
CUI: C4551488
Disease: Bifid uvula
Bifid uvula 		0.100 Biomarker disease HPO
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 AlteredExpression disease BEFREE However, high SIX3 mRNA level was a protective factor for OS and RFS of basal-like breast cancer patients.Our study suggested that members of SIX family played distinct roles in breast cancer. 27399099 2016
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE We demonstrate that the SIX3/LSD1/NuRD(MTA3) complex inhibits carcinogenesis in breast cancer cells and suppresses metastasis in breast cancer. 29463994 2018
CUI: C0007120
Disease: Bronchioloalveolar Adenocarcinoma
Bronchioloalveolar Adenocarcinoma 		0.010 AlteredExpression disease BEFREE Moreover, SIX3 mRNA expression was associated with significantly improved overall survival (OS) and progression-free survival (PFS) in adenocarcinoma patients and patients with bronchioloalveolar carcinoma (BAC) features. 23977152 2013
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.050 Biomarker phenotype BEFREE Little is known about the role of SIX3 in human tumorigenesis. 23977152 2013
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.050 Biomarker phenotype BEFREE However, studies on the function of SIX3 in human tumorigenesis remain rare. 30672777 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.050 Biomarker phenotype BEFREE However, little is known about the role of Six3 in human tumorigenesis. 28643150 2017
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.050 Biomarker phenotype BEFREE We demonstrate that the SIX3/LSD1/NuRD(MTA3) complex inhibits carcinogenesis in breast cancer cells and suppresses metastasis in breast cancer. 29463994 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.050 AlteredExpression phenotype BEFREE Importantly, interactions between AURKA and AURKB stabilize and protect AURKA/B from degradation, and overexpression of SIX3 does not affect these interactions; SIX3 also acts as a tumor suppressor, and it increases p53 activity and expression at the post-translational level by the negative regulation of AURKA or AURKB, reduces the events of numerical centrosomal aberrations and misaligned chromosomes, and significantly inhibits the proliferation, invasion, and tumorigenesis of astrocytoma in vitro and in vivo. 28595628 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.010 Biomarker disease BEFREE Wound healing assays were used to assess cell migration, and microarrays were utilized to examine genes regulated by SIX3 in lung cancer cells. 23977152 2013